A total of 353 patients were screened for eligibility; 74 were excluded for the following reasons: prior treatment with other anti-VEGF agents at baseline before bevacizumab treatment (n = 4), pre-existing proteinuria (n = 22), baseline eGFR < 30 mL/min/1.73 m2 (n = 9), history of diabetes, dyslipidemia, cardiovascular diseases and stroke (n = 31), and incomplete clinical data (n = 12), with overlap. This evidence concerns the gene VEGFA and metabolic syndrome.